普罗布考对不稳定型心绞痛患者血清明胶酶的影响.doc

普罗布考对不稳定型心绞痛患者血清明胶酶的影响 　　作者：刘春辉,贺兆发,乔峰　　作者单位：佳木斯大学附属第一医院心内科， 黑龙江 佳木斯 　　【摘要】目的：探讨普罗布考对不稳定型心绞痛(UAP)患者血清明胶酶的影响。方法：连续入选UAP患者80例，随机分为普罗布考治疗组(40例)和常规治疗组(40例)。常规治疗组采用硝酸酯类、阿司匹林、Β受体阻滞剂等常规药物治疗;普罗布考组在常规治疗基础上加用普罗布考口服，观察治疗前及治疗一个月后血清明胶酶水平。结果：与治疗前比较，普罗布考治疗组治疗后基质金属蛋白酶(MMP)-2[(54.04±6.54) ng/ml比(32.43±1.81) ng/ml]、MMP-9[(56.33±7.25) ng/ml比(34±1.45) ng/ml]水平均明显下降 (P均0.01)，且明显低于常规治疗组治疗后[MMP-2：(37.21±2.86) ng/ml、MMP-9：(39.96±1.75) ng/ml]，P0.05。结论：普罗布考能促进不稳定型心绞痛患者血清明胶酶水平的下降，起到稳定粥样斑块的作用。 　　【关键词】 普罗布考,心绞痛,不稳定型;明胶酶类 　　Abstract：Objective： To investigate effects of probucol on serum levels of gelatinases in patients with unstable angina pectoris (UAP). Methods： A total of 80 UAP patients were continuously enrolled and randomly divided into probucol treatment group (n=40) and routine treatment group (n=40). Routine treatment group was given routine medical treatment with nitrates， aspirin and Β-receptor blocker etc; probucol group was given probucol oral additionally based on routine treatment. Serum levels of gelatinases were examined before and one month after treatment. Results： Compared with before treatment， levels of matrix metalloproteinase (MMP)-2 [(54.04±6.54) ng/ml vs. (32.43±1.81) ng/ml] and MMP-9 [(56.33±7.25) ng/ml vs. (34±1.45) ng/ml] significantly decreased in probucol treatment group after treatment (P0.01 both)， and significantly lower than those of routine treatment group [MMP-2： (37.21±2.86) ng/ml， MMP-9： (39.96±1.75) ng/ml]， P0.05. Conclusion： Probucol could decrease serum levels of gelatinases in patients with unstable angina pectoris， and possess effect of stabilization of atherosclerotic plaque. 　　Key words：Probucol; Angina， unstable; Gelatinases 　　普罗布考即丙丁酚，是目前公认的最具有前途的抗氧化剂。近年来大量研究表明普罗布考具有稳定和消退斑块，改善血管内皮功能，抑制血管成形术后再狭窄等作用，故其在临床的应用受到了人们的重视。本研究观察普罗布考对不稳定型心绞痛(UAP)患者血清明胶酶(包括基质金属蛋白酶-2及基质金属蛋白酶-9)的影响，进一步明确抗氧化剂普罗布考稳定粥样斑块作用的机制，为临床应用提供理论依据。 　　1　资料与方法 　　1.1　研究对象 　　连续入选2010年9月至2011年1月在我院住院的UAP患者80例。诊断标准均符合中华心血管学会诊断标准。UAP患者被随机分为两组：普罗布考治疗组40例，男22例，女18例，